Midatech Pharma PLC (LON:MTPH)‘s stock had its “buy” rating reaffirmed by research analysts at Panmure Gordon in a research note issued to investors on Tuesday. They currently have a GBX 297 ($3.71) target price on the stock. Panmure Gordon’s price objective suggests a potential upside of 145.45% from the company’s current price.

Separately, N+1 Singer reaffirmed a “buy” rating and issued a GBX 283 ($3.54) target price on shares of Midatech Pharma PLC in a research note on Monday, October 31st.

Midatech Pharma PLC (LON:MTPH) opened at 120.4738 on Tuesday. Midatech Pharma PLC has a 1-year low of GBX 100.51 and a 1-year high of GBX 270.00. The company has a 50-day moving average of GBX 121.96 and a 200-day moving average of GBX 131.66. The firm’s market capitalization is GBX 40.41 million.

ILLEGAL ACTIVITY NOTICE: This report was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this report can be read at https://www.thecerbatgem.com/2016/11/24/midatech-pharma-plc-mtph-rating-reiterated-by-panmure-gordon-2.html.

About Midatech Pharma PLC

Midatech Pharma PLC is an early-stage biopharmaceutical company that focuses on commercializing and developing products in oncology and other therapeutic areas. The Company’s segments include Pipeline Research and Development, and Commercial. The Pipeline Research and Development segment seeks to develop products using the nanomedicine and sustained release technology platforms.

Receive News & Stock Ratings for Midatech Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Midatech Pharma PLC and related stocks with our FREE daily email newsletter.